Report Date: Wednesday, August 5, 2026, after market close Fiscal Quarter: Q1 FY2027 (quarter ended June 30, 2026)
MCK shares have had a strong run into earnings, climbing from roughly $735 in early May to an all-time high near $889 in late July before pulling back to the $827-$830 range in the days before the print. Analysts have generally been raising price targets throughout the summer — Citi lifted its target to $1,000 from $945 on July 23, and the average Street price target sits in the $935-$1,005 range against a "Strong Buy"/"Buy" consensus rating, though a handful of firms (Barclays, Deutsche Bank, BofA) trimmed targets earlier in the year on mixed revenue optics.
The stock trades at a premium multiple versus peers Cencora and Cardinal Health, which the market has justified with McKesson's forward 12-month price-to-sales multiple reflecting a premium relative to its MedTech peers, as investors assign higher valuation to the company's long-term growth prospects, particularly its specialty expansion and productivity gains from automation and AI investments. That premium raises the bar for tomorrow's results — any disappointment on revenue or segment margins could trigger an outsized reaction given how much good news is now priced in.
Management's own FY2027 framework calls for adjusted EPS of $43.80–$44.60 (+12-14% y/y, or 14-16% excluding one-time items), consolidated revenue growth of 5-9%, and adjusted operating profit growth of 8-12% for the full year — so Q1 is the first data point testing that cadence.
North American Pharmaceutical (the core distribution engine): Guided to FY27 revenue growth of 4-8% and operating profit growth of 5.5-9.5%. Key swing factors: - GLP-1s: GLP-1 distribution revenue grew in the mid-20% range over the last several years but declined sequentially in Q4 (down 4% quarter-over-quarter even as it still grew 22% y/y). Watch whether that sequential softness persists or reaccelerates. - Branded pricing/IRA: Management flagged that lower branded pharmaceutical revenue, reflecting declines in manufacturer prices on certain products, reduced year-over-year revenue growth by approximately 3% in the fourth quarter, and this will now be a full-year headwind comparison. This is arguably the single biggest revenue-vs-margin nuance for the model this quarter. - Biosimilars: Management continues to frame the Part B/Part D biosimilar wave as a net positive for distribution economics, calling it "a win-win-win," even as investors probe the buy-margin impact from falling ASPs.
Oncology & Multispecialty (the growth pillar): Guided to FY27 revenue growth of 14.5-18.5% and operating profit growth of 13.5-17.5%, with organic growth running "right around 13%" underneath the acquisition contribution from PRISM Vision and Core Ventures. Watch for continued provider network additions (U.S. Oncology Network added over 570 providers in FY26, the largest increase since 2010) and commentary on the recently added Cancer Care Northwest and Retina Macula Institute practices.
Prescription Technology Solutions (RxTS): Guided conservatively to revenue growth of just 2.5-6.5% (slower than historical trends) but operating profit growth of 11-15% — at the upper end of the long-term target range. This segment's revenue is lumpy and driven by 3PL program timing (roughly 55% of segment revenue), so investors should focus on operating profit/margin trajectory rather than the headline revenue growth rate.
Medical-Surgical Solutions (separation in progress): This is the key structural story of FY2027. Recent milestones include: - Apollo Funds closing on a $1.25 billion convertible preferred investment for ~13% of MMS, valuing the segment at ~$13 billion enterprise value. - Establishment of an independent capital structure via a $1 billion Term Loan A and $1 billion revolver, with up to $2.25 billion of additional term loans expected to be issued in Q1 FY27, proceeds of which are earmarked "principally toward share repurchases." - Management targets an MMS IPO in the second half of calendar 2027, contingent on market conditions and regulatory approval, with an eventual tax-free spin-off/split-off of McKesson's remaining stake. Investors will want an update on financing execution, transition-service-agreement progress, and any timeline commentary on the call.
McKesson enters the year with significant repurchase firepower: the board upsized total buyback authorization to $7.7 billion as of April 2026, and management guided to roughly $5 billion of share repurchases in FY2027, partly funded by MMS-related financing proceeds. The company also raised its quarterly dividend 15% to $0.94/share in July, its most aggressive dividend hike in recent years, signaling continued confidence in cash generation. FY2027 free cash flow is guided to $4.5-4.9 billion, a step down from FY2026's $5.4 billion (which benefited from working-capital timing), so the shape of Q1 cash flow will be watched for confirmation that the guide is conservative rather than a sign of deteriorating conversion.
This is the first earnings call under new CFO Kenny Cheung, who succeeded longtime CFO Britt Vitalone (retiring after 20 years, 8+ as CFO) effective May 29, 2026. Vitalone remains as a strategic advisor through the MMS separation. Watch for any shift in tone, disclosure style, or guidance philosophy under new financial leadership, as well as continuity messaging on capital allocation priorities.
McKesson carries $5.7 billion of total opioid-related litigation liabilities on the balance sheet as of March 31, 2026 ($601 million current, $5.09 billion long-term), down from $6.4 billion a year earlier as settlement escrow payments continue. On the positive side, a Maryland Supreme Court ruling vacated a $152 million jury verdict against McKesson and Cencora, leading Baltimore City to drop its opioid case entirely in May 2026 — a modest positive legal precedent, though hundreds of other private-plaintiff opioid cases remain outstanding and are excluded from existing settlement charges.
McKesson goes into this print near all-time highs, priced for continued execution on its highest-growth platforms (oncology, biopharma services) and successful de-risking of the Medical-Surgical separation. The setup is a "high expectations, high multiple" situation: revenue has missed consensus in recent quarters even as adjusted EPS beat, so investors should watch the quality of the beat (segment margins, oncology organic growth, RxTS profit conversion) rather than the headline revenue number alone. Confirmation of the FY2027 guide, further clarity on MMS separation timing, and stabilization in GLP-1/branded-pricing trends would likely be the biggest swing factors for the stock's next leg.